Peptidera-afbeelding bij onderzoek naar VIP; illustratieve productweergave

VIP in experimental arthritis: inflammation in an animal model

Peptidera image from research on VIP; illustrative product display
Existing Peptidera product image for illustration; not a photograph or measurement result from the study.

Evidence level: Animal research: experimental autoimmune arthritis · Publication year: 2001

This overview discusses one original scientific publication on VIP. The source is indexed in PubMed, the literature database of the U.S. National Library of Medicine.

What was studied?

The researchers studied VIP in an experimental arthritis model and examined both inflammatory processes and the autoimmune component of the disease.

What did the researchers find?

The study reported a lower incidence and severity of arthritis, with less joint swelling and less damage to cartilage and bone in the model used.

What are the limitations?

Animal models only replicate some aspects of human rheumatoid arthritis. The publication does not prove the efficacy or safety of VIP as a treatment in humans.

Significance for research

Here, VIP was studied as a signaling peptide in a specific immune model, not as a general anti-inflammatory agent for every application.

Official source

Original publication via PubMed — PMID 11329057 · DOI: 10.1038/87887

Research Use Only. This literature summary does not contain treatment or usage advice. Research on a molecule is not evidence of the efficacy, safety, or purity of a Peptidera product. PubMed indexing is not product approval.

Related research products

View product specifications and available batch documentation. The studies discussed were not conducted using Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.

Back to blog

Leave a comment

Please note, comments need to be approved before they are published.